ERFURT and BERLIN, Germany, November 30th, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) is proud to present the second episode of its “Round Table” series with Dr. Wieland Schinnenburg, MdB of the FDP, who provides an up-to-date overview of the political issues and challenges facing the medical cannabis in Germany. In addition, the discussion panel will share their views on how the industry will change for companies operating in the sector over the next decade.
Episodes of the Round Table Series can be found on AMP’s website: www.amp-eu.de/roundtable (in German with English subtitles), AMP’ YouTube channel and by all major podcast platforms (in German).
AMP Round Table Series, Episode #2: “Politics and Medical Cannabis in Germany”
Medical cannabis has been an important political issue even before Germany legalized its use three years ago and is becoming even more relevant in current politics.
The majority of the political parties in Germany are in agreement that medical cannabis has a role in benefiting some medical conditions. However, German politicians and the public would agree that policies enacted since legalization have room for improvement. Open issues like patient access, medical conditions covered, guaranteed health insurance coverage for medical cannabis prescriptions and sources of supply still need to be addressed.
In AMP Round Table Episode #2, Dr. Wieland Schinnenburg, MdB, spokesman for drug and addiction policy of the Free Democratic Party (FDP) and a well-respected medical cannabis expert joins Dr. Stefan Feuerstein to discuss the politics of medical cannabis as well as the opportunities and challenges facing medical cannabis companies like AMP.
Dr. Schinnenburg will discuss how the government will address the aforementioned issues in the near future in addition to:
Summary of Topics Discussed
• How do the political parties’ views differ on medical cannabis in Germany?
• How do the German federal government and the sixteen German states view medical cannabis?
• Can supplying the growing demand for medical cannabis in Germany be better managed?
• What can be learned from the first domestic cultivation tender in regard to how the process was conducted and in meeting the growing demand for medical cannabis?
• What role can imported medical cannabis play in meeting the current and growing demand for medical cannabis?
• Could an increase in imported medical cannabis improve competition in Germany and lower prices to health insurance companies and private patients?
• How are policies at the Cannabis Agency at German’s Federal Institute for Drugs and Medical Devices (BfRaM) being made?
• How will the medical cannabis industry develop in Germany over the next five to ten years from now?
Dr. Wieland Schinnenburg MdB, (FDP)
Dr. Schinnenburg studied dentistry from 1978 to 1984 at the Medical University of Hannover and the Westphalian Wilhelms University in Münster. After his state examination, he received his doctorate in 1985 and worked as an employed dentist from 1984 to 1987. From 1987 until his election to the German Bundestag in 2017, he ran his own practice in Oststeinbek near Hamburg.
In addition to his work as a dentist, he began studying law at the University of Hamburg in 1989, which he completed in 1994 with the First State Examination; in 1997, he took the Second State Examination at the Higher Regional Court of Celle. During his studies, he completed study visits and internships in Port-au-Prince, Los Angeles, Chiang Mai, Jerusalem and Washington, D.C. In 1998, Dr. Schinnenburg opened a law firm in addition to his dental practice. Since 2006, Dr. Schinnenburg has been a specialist lawyer for medical law and since 2007 a mediator.
Dr. Stefan Feuerstein (AMP)
Dr. Feuerstein is Director and President of AMP and has over three decades of experience in facilitating and leading investment opportunities from within and outside of Germany. Dr. Feuerstein served as managing director of IIC Industrial Investment Council GmbH, which acted as an investment promotion agency for the five Eastern German States, including Berlin. He also served as managing director of the TLW Thüringer Landeswirtschafts-Förderungsgesellschaft, Erfurt, or the German State of Thuringia Economic Department.
Mr. Holger Scholze (Round Table Moderator)
Mr. Holger Scholze is a German television stock market analyst, lecturer, and presenter. Mr. Scholze became known to a large audience primarily through his more than 5,000 live broadcasts as a correspondent for the German national news channel, n-tv. Mr. Scholze has been dealing with the international financial markets for thirty years and has been regularly assessing the current market situation for two decades for various TV and radio stations.
About Jushi Europe (Round Table Sponsor)
Round Table Episode #2 is sponsored by Jushi Europe SA, the European subsidiary of Jushi Holdings Inc. (CSE: JUSH, OTCMKTS: JUSHF) and headquartered in Switzerland. Jushi Europe’s strategy is focused on building large-scale production in Portugal for export to the European medical cannabis market. Jushi Europe represents geographic diversification of the Jushi portfolio and an entrance into early-stage cannabis markets through long-term investments.
About AMP German Cannabis Group
AMP German Cannabis Group is licensed to import European Union – Good Manufacturing Practice (EU-GMP) medical cannabis from Europe and elsewhere into Germany. AMP sources, stores,
transports, delivers, and sells medical cannabis products to pharmaceutical distributors or pharmacists directly, the only point-of-sale for medical cannabis to German patients with a physician’s prescription. For more information, please visit: www.amp-eu.com
Mr. Alex Blodgett, CEO and Director
Telephone: +1 236-833-1602
AMP social media links:
• Twitter: https://twitter.com/AMP_Cannabis
• LinkedIn: www.linkedin.com/company/ampgermancannabisgroup
• Facebook: www.facebook.com/AMPGCG
• Instagram: www.instagram.com/ampgcg
• Podcast: http://ow.ly/EqBc50BJ4xw
Media Kit: www.amp-eu.com/media-kit
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
SOURCE: AMP German Cannabis Group Inc.